[go: up one dir, main page]

WO2010042742A3 - Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser - Google Patents

Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser Download PDF

Info

Publication number
WO2010042742A3
WO2010042742A3 PCT/US2009/060038 US2009060038W WO2010042742A3 WO 2010042742 A3 WO2010042742 A3 WO 2010042742A3 US 2009060038 W US2009060038 W US 2009060038W WO 2010042742 A3 WO2010042742 A3 WO 2010042742A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
same
nucleic acid
core protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/060038
Other languages
English (en)
Other versions
WO2010042742A2 (fr
Inventor
Miguel De Los Rios
John Mendlein
Timothy L. Bullock
Kenneth J. Oh
Patrick T. Johnson
Jacek Ostrowski
Stephanie De Los Rios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chimeros Inc
Original Assignee
Chimeros Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimeros Inc filed Critical Chimeros Inc
Publication of WO2010042742A2 publication Critical patent/WO2010042742A2/fr
Publication of WO2010042742A3 publication Critical patent/WO2010042742A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des agents thérapeutiques comprenant une protéine centrale virale modifiée et un acide nucléique lié à cette protéine centrale virale modifiée. Dans certains modes de réalisation, l'acide nucléique peut être sensiblement homologue d'une cible d'un gène spécifique. Dans certains modes de réalisation, l'acide nucléique lié à la protéine centrale virale modifiée est essentiellement non-immunogène.
PCT/US2009/060038 2008-10-08 2009-10-08 Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser Ceased WO2010042742A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10383508P 2008-10-08 2008-10-08
US61/103,835 2008-10-08

Publications (2)

Publication Number Publication Date
WO2010042742A2 WO2010042742A2 (fr) 2010-04-15
WO2010042742A3 true WO2010042742A3 (fr) 2010-10-14

Family

ID=42101212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/060038 Ceased WO2010042742A2 (fr) 2008-10-08 2009-10-08 Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser

Country Status (1)

Country Link
WO (1) WO2010042742A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017473A2 (fr) 2006-08-08 2008-02-14 Gunther Hartmann Structure et utilisation d'oligonucléotides 5'-phosphate
WO2009141146A1 (fr) 2008-05-21 2009-11-26 Gunther Hartmann Oligonucléotide à 5’-triphosphate présentant une extrémité franche et ses utilisations
EP2508530A1 (fr) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification d'oligonucléotides triphosphorylés au moyen d'étiquettes de capture
EP2712870A1 (fr) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Nouveaux ligands de RIG-I et procédés pour les produire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442394B1 (fr) * 1990-02-16 2000-08-16 United Biomedical, Inc. Peptides synthétiques spécifiques pour la détection d'anticorps contre HVC et diagnostic des infections par HVC
US6235284B1 (en) * 1992-05-06 2001-05-22 Bio Merieux Synthetic polypeptides belonging to the hepatitis C virus (HCV) and which can be used especially for detecting the latter
WO2004042001A2 (fr) * 2002-05-17 2004-05-21 Emory University Particules pseudovirales, procede de fabrication et compositions immunogeniques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442394B1 (fr) * 1990-02-16 2000-08-16 United Biomedical, Inc. Peptides synthétiques spécifiques pour la détection d'anticorps contre HVC et diagnostic des infections par HVC
US6235284B1 (en) * 1992-05-06 2001-05-22 Bio Merieux Synthetic polypeptides belonging to the hepatitis C virus (HCV) and which can be used especially for detecting the latter
WO2004042001A2 (fr) * 2002-05-17 2004-05-21 Emory University Particules pseudovirales, procede de fabrication et compositions immunogeniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOO HO CHOI ET AL.: "Hepatitis C Virus Core Protein Is Efficiently Released into the Culture Medium in Insect Cells", JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 37, no. 6, November 2004 (2004-11-01), pages 735 - 740 *

Also Published As

Publication number Publication date
WO2010042742A2 (fr) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2010042749A3 (fr) Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser
WO2010042755A3 (fr) Agents thérapeutiques chimères, compositions et méthodes d'utilisation
WO2010042751A3 (fr) Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser
WO2012045082A3 (fr) Synthèse d'acides nucléiques et méthodes d'utilisation associées
WO2009149956A3 (fr) Protéine de fusion et son utilisation
WO2009042186A3 (fr) Edition génomique dans un dard-perche à l'aide de nucléases à doigt de zinc
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
GB2470672B (en) Methods of RNA amplification in the presence of DNA
WO2010127304A3 (fr) Procédés de séquençage
WO2010062480A3 (fr) Procédés et compositions pour la production d'alcools gras
WO2012112730A3 (fr) Compositions et procédés pour délivrer un acide nucléique à une cellule
WO2009120374A3 (fr) Procédés et compositions pour la préparation d’échantillon d’acide nucléique
WO2011005799A3 (fr) Molécules d'arn autorépliquantes et leurs utilisations
WO2009126250A3 (fr) Reprogrammation d’une cellule par induction d’un gène pluripotent par interférence arn
EP4397760A3 (fr) Composition pour le clivage d'un adn cible comprenant un arn guide spécifique de l'adn cible et un acide nucléique codant pour la protéine cas ou la protéine cas, et leur utilisation
WO2009099641A3 (fr) Compositions protéiniques stabilisées
WO2011072246A3 (fr) Modification de l'adn induite par l'effecteur tal
MX343221B (es) Composiciones y metodos que comprenden variantes de celulasa con afinidad reducida a materiales no celulosicos.
IL188202A0 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2008067423A3 (fr) Procédé d'amélioration de l'introduction d'adn dans des cellules bactériennes
WO2010120874A3 (fr) Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation
WO2010039802A3 (fr) Procédés et compositions pour isoler un acide nucléique
WO2011153276A3 (fr) Enzymes cellobiohydrolases chimères fonctionnelles et stables de classe i
WO2009099877A3 (fr) Vecteurs de closterovirus et procédés
WO2012024573A3 (fr) Compositions comprenant des cellules souches périvasculaires et la protéine nell-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09819898

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 01-08-2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09819898

Country of ref document: EP

Kind code of ref document: A2